Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3525 in relapsed/refractory peripheral T-cell lymphoma
CTR20202036Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQ-B3525 in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Aug 2022; status: terminated.
02
Drugs
TQ-B3525
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on CTR20202036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202036.